# 2026-10010: Company Officially Becomes Itself LLC in Drug Probe

2026-10010, Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation, is a Federal Register notice from International Trade Commission published 2026-05-19, effective 2026-05-15 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-10010
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-10010
- Title: Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation
- Type: Notice
- Agencies: International Trade Commission
- Citation: 91 FR 29169
- Published: 2026-05-19
- Effective: 2026-05-15
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Company Officially Becomes Itself LLC in Drug Probe

## Summary

The U.S. International Trade Commission has approved updating the investigation papers to reflect that Ascendis Pharma changed its name to Ascendis Pharma, LLC. This affects companies involved in a patent dispute over certain drug products with C-type natriuretic peptide variants. No delays or extra costs are expected, so the investigation keeps moving forward smoothly.

## Abstract

Notice is hereby given that the U.S. International Trade Commission ("Commission") has determined not to review an initial determination ("ID") (Order No. 45) of the presiding Chief administrative law judge ("Chief ALJ") granting complainant's unopposed motion to amend the complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.'s corporate name change to Ascendis Pharma, LLC.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-22911](https://policyrisk.com/federal-register/2026-22911): Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest, 2026-11-10
- [2026-22904](https://policyrisk.com/federal-register/2026-22904): Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest, 2026-11-10
- [2026-22923](https://policyrisk.com/federal-register/2026-22923): Prestressed Concrete Steel Wire Strand From China; Determinations, 2026-11-10
- [2026-22768](https://policyrisk.com/federal-register/2026-22768): Certain Glow Fish Tape Systems, Safety Helmet Systems, and Components Thereof; Notice of a Final Determination Finding a Violation of Secti…, 2026-11-09
- [2026-22730](https://policyrisk.com/federal-register/2026-22730): Certain Foundry Coke; Notice of a Commission Determination Not To Review an Initial Determination Granting Complainants' Motion To Amend th…, 2026-11-09
- [2026-22595](https://policyrisk.com/federal-register/2026-22595): Seamless Refined Copper Pipe and Tube From Vietnam; Scheduling of an Expedited Five-Year Review, 2026-11-05

## Sources
- [2026-10010 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/19/2026-10010/certain-drug-products-containing-c-type-natriuretic-peptide-variants-and-components-thereof-notice)
- [2026-10010 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-19/pdf/2026-10010.pdf)

## Related
- [Previous: 2026-10009, Sunshine Act Meetings](https://policyrisk.com/federal-register/2026-10009)
- [Next: 2026-10012, Advisory Committee on Immunization Practices (ACIP); Notice of Charter Re-Estab…](https://policyrisk.com/federal-register/2026-10012)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-10010 (as of 2026-06-08).
